The expression and clinical signiciance of Survivin and Fas/FasL in non-small cell lung cancer

Abstract

Objective To detect the expression of Survivin, Fas/FasL in non-small cell lung cancer(NSCLC) tissue. Methods We used immunohistochemistry to detect the expression of Survivin, Fas/FasL in 16 cases of normal lung, 48 cases of squamous carcinoma of lung tissue, 38 cases of adenocarcinoma of lung tissue. Results The positive rate of Survivin in normal lung tissue, squamous carcinoma and adenocarcinoma of lung were 0, 79.17% and 70.05% respectively, and there was significant difference between the normal and the two NSCLC groups(P<0.01). The positive rate of Fas in normal lung tissue(81.25%) was significantly higher than that in squamous carcinoma of lung(41.76%) and adenocarcinoma of lung(43.37%),P<0.05. The positive of FasL in normal lung tissue(18.75%) was significantly lower than that in SqCa(72.92%) and adenocarcinoma of lung(68.42%)(P<0.05). No relation was found between the expression of FasL and clinicopathologic factors including sex, histoclassification. And there was a relation between lymphnode metastasis and TNM stage of NSCLC. Conclusions Apoptosis inhibitition caused by abnormal survivin expression may participate in the onset and progression of NSCLC. The over-expression survivin suggests the bad prognosis in NSCLC. The expression of Fas protein in NSCLC was low, and might play a role in carcinogenesis of lung carcinoma. The expression of Fas/FasL in NSCLC may play an important role in the escape of tumor cells from immune function. The expression of FasL might be used as an objective indicator of metastasis potency of local lymph node. Key words: Non-small cell lung cancer ; Survivin,Fas/FasL ; Immunohistochemistry ;